IMPACT Therapeutics Gains Positive CHMP Opinion for Senaparib
NANJING, China and BASILDON, UK — September 18, 2026 IMPACT Therapeutics and Pharmanovia announced that the Committee for Medicinal...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
NANJING, China and BASILDON, UK — September 18, 2026 IMPACT Therapeutics and Pharmanovia announced that the Committee for Medicinal...
SHANGHAI, July 31, 2026 IMPACT Therapeutics announced an exclusive licensing agreement with Pharmanovia, granting the global specialty pharmaceutical company...
